Pasithea Therapeuticsの空売り状況は、投資家がPasithea Therapeuticsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Pasithea Therapeutics (NASDAQ:KTTA) 株価情報, 空売り情報

Pasithea Therapeutics

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics Corp

WIIM

ATOM

Atomera shares are trading higher. The company reported Q1 financial results.

Datadog Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) Tuesday announced <a href="https://www.benzinga.com/news/earnings/25/05/45221686/datadog-tops-q1-estimates-raises-revenue-outlook-flags-margin-pressure">upbeat first-quarter revenues</a>.
Here are some key analyst takeaways.
<ul>
<li>Wedbush <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e00ad4e3513fb0001f03cfd/daniel-ives">analyst Daniel Ives</a> maintained an Outperform rating, while reducing the price target from $155 to $140.</li>
<li>Needham <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/601a8839a6fe6f00010c6966/mike-cikos">analyst Mike Cikos</a> reaffirmed a Buy rating, while cutting the price target from $160 to $130.</li>
<li>Cantor Fitzgerald <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/61e7dac6ecb07f0001d8956b/thomas-blakey">analyst Thomas Blakey</a> reiterated an Overweight rating and price target of $134.</li>
<li>Goldman Sachs <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58c6ab8db85e9300015f1ae0/kash-rangan">analyst Kash Rangan</a> maintained a Buy rating and price target of $127.</li>
</ul>
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Wedbush: Datadog reported its first-quarter results with "beats across the board," Ives said in a note. Bookings were strong during the quarter, with RPO (remaining performance obligations) coming in at $2.31 billion, up 33% year-on-year.
Management raised their 2025 revenue guidance to a range of $3.215 billion to $3.235 billion, above the Street's $3.20 billion estimate, as the company "maintains a solid pipeline across its entire customer base for cloud migration and digital transformation projects," Ives stated. 
However, the operating margin guidance of $625 million to $645 million came in below the Street's $680.3 million estimate, Ives noted. The company is ramping up hiring plans while looking for &#8220;cost efficiencies in its cloud costs.&#8221;
Needham: Datadog reported solid quarterly results and guided to second-quarter revenue above consensus, Cikos said. 
Datadog's sales representative headcount grew by more than 25% year-on-year, "with a greater emphasis on the Enterprise segment and International," he added.
Management indicated that AI-Natives had risen to 8.5% of ARR (annual recurring revenues), the analyst stated. However, the company lowered its 2025 operating profit guidance by $30 million "to account for $15 Million in OpEx tied to currency and $10 Million from the Eppo and Metaplane acquisitions," he further wrote.
Cantor Fitzgerald: Datadog reported strong first-quarter results. Its AI native cohort drove momentum. Plus, record levels of new logo bookings grew 70% year-over-year, Blakey wrote in a note. The company generated total revenue growth of 24.6%, higher than consensus expectations.
Management raised their full-year revenue guidance by $40 million, despite the first-quarter beat being $23 million. "We continue to believe Datadog is a unique asset in software, with market leadership in a strategically growing market centered on cloud-focused observabiltiy including AI," Blakey added.
Goldman Sachs: Datadog's NRR trended in the high 110s for a second straight quarter, Rangan said. The stock came under pressure due to the company's gross margins coming in below consensus and the second consecutive quarter of weaker-than-expected operating margin guidance for the full year.
"We view AI Revenue driven largely by inference as a positive, given this revenue stream's sustainability should ease investors' concerns around topline volatility," Rangan wrote.
DDOG Price Action: At the time of publication on Wednesday, shares of Datadog had declined by 0.89% to $105.12.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/25/04/45045012/sabre-divests-hospitality-arm-tpg-plans-debt-reductioncore-platform-focus">These Analysts Revise Their Forecasts On Datadog After Q1 Results</a> </li>
</ul>
Image: Shutterstock

Analyst Color

Earnings Beats

Price Target

Reiteration

Analyst Ratings

DDOG

Datadog Lifts Revenue Outlook, Analysts Still Bark About Margins

SNCR

Synchronoss Technologies shares are trading lower after the company reported worse-than-expected Q1 financial results and issued FY25 sales guidance below estimates.

Macro Notification

General

AVGO

NVDA

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

Shares of chip stocks are trading higher following a report indicating President Trump will rescind global chip curbs.

ACET

Adicet Bio shares are tracing lower. The company reported Q1 financial results.

<a href="https://www.bloomberg.com/news/articles/2025-05-07/trump-to-rescind-global-chip-curbs-amid-ai-restrictions-debate" title="https://www.bloomberg.com/news/articles/2025-05-07/trump-to-rescind-global-chip-curbs-amid-ai-restrictions-debate">https://www.bloomberg.com/news/articles/2025-05-07/trump-to-rescind-global-chip-curbs-amid-ai-restrictions-debate</a>

Macro Economic Events

News

Global

Economics

ASML

INTC

LRCX

LSCC

NXPI

RMBS

'Trump To Rescind Global Chip Curbs Amid AI Restrictions Debate' - Bloomberg News

<a href="https://fortune.com/2025/05/07/green-dot-walmart-apple-prepaid-debit-cards-private-equity-citigroup-fintech-banks/" title="https://fortune.com/2025/05/07/green-dot-walmart-apple-prepaid-debit-cards-private-equity-citigroup-fintech-banks/">https://fortune.com/2025/05/07/green-dot-walmart-apple-prepaid-debit-cards-private-equity-citigroup-fintech-banks/</a>

GDOT

'Fintech Giant Green Dot Attracts Private Equity Interest Despite Sluggish Deal Climate' - Fortune

Doubleline Capital's Gundlach Says As The Economy Weakens, Long Term Interest Rates Could Very Well Be Going Above; We're In A Risk-Off Market On Intermediate Term Basis; I Do Think The Fed Will Probably Cut Rates By Year End

On May 1, 2025, Rani Therapeutics Holdings, Inc. ("Company") received a letter ("Notice") from the Nasdaq Stock Exchange LLC ("Nasdaq"), addressing a compliance deficiency under the Nasdaq Listing Rules. The letter notified of the deficiency with regard to Rule 5450(b)(2)(A), which requires a company whose securities are listed on The Nasdaq Global Market under the "Market Value Standard" to maintain a minimum Market Value of Listed Securities (an "MVLS") of $50,000,000. The deficiency was caused by the Company's MVLS having been below the minimum level for the prior 30 consecutive business days.

RANI

Rani Therapeutics Says On May 1, 2025 It Received A Letter Of Non-Complaisance From Nasdaq

RIGL

RIGL stock has given up its prior gain. Rigel Pharmaceuticals shares were trading higher after the company reported Q1 financial results and beat its EPS and sales estimates.

Movers

Trading Ideas

NTCL

NETCLASS TECHNOLOGY Shares Halted For Volatility

At their meeting held today, the Board of Directors of Chesapeake Utilities Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPK#NYSE">CPK</a>) voted to increase the quarterly cash dividend on the Company's common stock from $0.64 per share to $0.685 per share. The Board's action raises the 2025 annualized dividend by $0.18 from $2.56 to $2.74 per share, a 7 percent increase. The $0.685 per share dividend will be payable July 7, 2025 to all shareholders of record at the close of business on June 16, 2025.

Dividends

Chesapeake Utilities Increases Quarterly Cash Dividend From $0.64 To $0.685/Shr; Ups Annualized Dividend By 7% From $2.56 To $2.74/Shr

IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) held its Think 2025 event in <a href="https://www.benzinga.com/25/05/45259042/ibm-thinks-big-ai-delivers-bigger-why-bulls-are-charging-toward-300">Boston on Tuesday. </a> 
The key takeaway from the event is the company's portfolio of software products and services being "integral to large enterprise customers as they leverage AI across their organizations," according to Goldman Sachs.
The IBM Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5805f8a2846faa000106ab15/james-schneider">Analyst James Schneider</a> maintained a Buy rating and price target of $270.
The IBM Thesis: The company launched LinuxONE 5, which enables 450 billion secure AI inference operations per day, Schneider said in the note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
The company also introduced an upgraded watsonx.data, which taps unstructured data to increase accuracy of AI agents, he added.
"CEO Arvind Krishna noted that AI is shifting from experimentation to delivering measurable business value, with an emphasis on productivity and cost efficiency," the analyst wrote.
IBM projected that AI agents could power 30% of the one billion new applications by 2028, he further stated.
By applying its AI solutions internally, the company can "support ongoing margin expansion and FCF growth &#8211; even as it executes on M&amp;A," Schneider said.
IBM Price Action: Shares of IBM were up 1.1% to $252.02 at the time of publication on Wednesday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45218573/ibms-ai-watsonx-integrates-with-oracle-cloud-to-boost-enterprise-productivity">IBM AI Watsonx Integrates With Oracle Cloud To Boost Enterprise Productivity</a></li>
</ul>
Photo: Shutterstock

Long Ideas

IBM's AI Push Takes Center Stage At Think 2025, Goldman Sees Path To Margin Growth

XChange TEC.INC shares are trading lower after the company announced plans to change its ADS ratio from 1-to-120 to 1-to-2400.

Hedge Funds

Doubleline Capital's Gundlach Says We're In A Risk-off Market On Intermediate Term Basis

GLBZ

Glen Burnie shares are trading lower after the company reported a year-over-year decrease in Q1 sales results.

Chardan Research initiated coverage on Praxis Precision Medicines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>) on Wednesday, citing the potential of its <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">epilepsy franchise</a>.
Analyst Rudy Li writes, &#8220;Epilepsy remains one of our favorite markets in the CNS space, and we view Praxis as a diversified play in epilepsy, with a portfolio of products leveraging validated drug targets.&#8221;
Praxis had $472.0 million in cash, cash equivalents, and marketable securities as of March 31, which is expected to fund operations into 2028.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40691948/praxis-precision-medicines-touts-encouraging-data-for-mid-stage-epilepsy-drug" rel="noreferrer noopener">Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug</a>
In March, Praxis released interim data from Study 1 of the Essential3 program of ulixacaltamide&nbsp;<a target="_blank" href="https://www.benzinga.com/25/03/44087912/analyst-cut-price-targets-for-praxis-precision-after-trial-setback-for-essential-tremor-candidate" rel="noreferrer noopener">in essential tremor (ET)</a>.
The Independent Data Monitoring Committee recommended stopping the study for futility. The results are unlikely to meet the primary efficacy endpoint.
<ul>
<li>&#8220;While we believe that the Phase 3 studies are unlikely to work (and we have not modeled for), we believe it is also possible that the FDA could provide regulatory flexibility given the unmet need for ET, which could provide additional upside to the story,&#8221; analyst Li writes.</li>
<li>In its first-quarter earnings release, the company said it decided to complete the studies and will share topline results in the third quarter of 2025. After reviewing the results of both studies, Praxis will decide if there is sufficient evidence to <a href="https://www.benzinga.com/pressreleases/25/05/g45164110/praxis-precision-medicines-provides-corporate-update-and-reports-first-quarter-2025-financial-resu" target="_blank" rel="noreferrer noopener">support an NDA filing</a>.</li>
</ul>
The analyst initiated with a Buy rating and a<a target="_blank" href="https://www.benzinga.com/quote/PRAX/analyst-ratings" rel="noreferrer noopener"> price forecast of $80</a>.
Chardan is optimistic <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37941441/why-praxis-precision-medicines-stock-is-trading-higher-tuesday" rel="noreferrer noopener">about vormatrigine&#8217;s (formerly PRAX-628) potential</a> in treating major types of epilepsy, especially focal onset seizures and generalized epilepsy, with possible peak sales over $1 billion.
<ul>
<li>As a next-generation sodium channel modulator, vormatrigine stands out from older drugs and current standard treatments because of its strong potency and targeted action, which could lead to better effectiveness and fewer side effects.</li>
<li>Early trials showed it has a wide safety margin, and a separate study showed high response rates in patients with light-triggered seizures.</li>
</ul>
Talking about Praxis&#8217;s elsunersen, an antisense product, Chardan writes that the product could become the first disease-modifying therapy for the treatment of SCN2A Gain-of-Function (GoF) DEE, which is a rare indication (~2K patients)
Price Action: PRAX stock is up 7.31% at $37.74 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/05/45257204/chinese-biotech-beigene-stock-falls-despite-strong-brukinsa-sales-and-earnings-beat" target="_blank" rel="noreferrer noopener">Chinese Biotech BeiGene Stock Falls Despite Strong Brukinsa Sales And Earnings Beat</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

Initiation

PRAX

Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside

DRCT

Direct Digital Holdings shares are trading lower after the company reported worse-than-expected Q1 financial results. Also, Benchmark lowered its price target on the stock from $8 to $6.

ASST

Asset Entities Shares Halted On Circuit Breaker To The Upside, Stock Now Up 345.9%

Applovin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) shares are facing selling pressure again after short seller Muddy Waters Research released a bearish report on the company, which follows an initial <a href="https://www.benzinga.com/trading-ideas/movers/25/03/44524167/applovin-shares-fall-20-following-muddy-waters-report-on-alleged-platform-violations-whats-going-on">short report from March</a>. 
What To Know: AppLovin shares sold off in March after Muddy Waters announced a short position, calling AppLovin &#8220;another scammy adtech company&#8221; that relies on retargeting for e-commerce conversions.
AppLovin executives responded to the short report in a <a href="https://www.applovin.com/blog/note-from-our-ceo-2/">blog post</a> that Muddy Waters says includes &#8220;demonstrably false&#8221; statements. The company also hired a law firm to perform &#8220;an independent review and investigation into recent short report activity targeting the Company.&#8221;
Muddy Waters on Wednesday alleged that AppLovin continues to use persistent identifiers that violate user privacy and partner&#8217;s terms of service, which AppLovin executives denied in a subsequent <a href="https://www.applovin.com/blog/how-we-drive-value-and-handle-data/">blog post</a>, the short seller said. 
Benzinga has reached out to AppLovin for comment on the report. 
&#8220;On March 31, Foroughi denied that APP creates or uses persistent identity graphs (PIGs) for users who decline IDFA cross &#8211; application tracking. On May 1, APP re-upped Foroughi's lie by recycling his March 31 post in a newsletter to stakeholders,&#8221; Muddy Waters said. 
&#8220;This presentation and the accompanying video show records of web and application traffic that prove these claims to be utterly false. We show that persistent identifiers are created, disguised, and applied to track users across domains and applications.&#8221;
The full short report can be found <a href="https://muddywatersresearch.com/wp-content/uploads/2025/05/MW_APP_20250507.pdf">here</a>. Benzinga&#8217;s previous coverage is also available via <a href="https://www.benzinga.com/trading-ideas/movers/25/03/44524167/applovin-shares-fall-20-following-muddy-waters-report-on-alleged-platform-violations-whats-going-on">this link</a>. 
AppLovin is due to report first-quarter financial results after the market close on Wednesday. Analysts expect the company to report earnings of $1.45 per share and revenue of $1.38 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. Investors will be watching for a potential response from the company in the earnings call, scheduled for 5 p.m. ET.
APP Price Action: AppLovin shares were down 2.4% at $297.30 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
AppLovin shares are down about 8% year-to-date, but the stock is still up more than 300% over a one-year period.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/05/45126778/short-seller-jim-chanos-slams-trumps-reindustrialization-hopes-says-3-per-hour-apple-supplier-foxconn-workers-were-too-expensive-questions-if-those-jobs">Short Seller Jim Chanos Slams Trump&#8217;s Reindustrialization Hopes: Says $3-Per-Hour Apple Supplier Foxconn Workers Were &#8216;Too Expensive&#8217; — Questions If &#8216;Those Jobs Are Coming Back&#8217;</a></li>
</ul>
Photo: Shutterstock.

Short Sellers

Muddy Waters Doubles Down On AppLovin In New Short Report Ahead Of Q1 Earnings

Press Releases

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4

Power Nickel's (TSX.V: PNPN) Hole Delivers "BIG"- Gold Terra (TSX.V: YGT) Developments and Exploration Progress Reported – More Stocks Inside!

Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients

Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004

Pasithea Therapeutics Announces Pricing of $5 Million Public Offering

KTTA

KTTAW

OGEN

PNPNF

TSXV:PNPN

TSXV:YGT

YGTFF

Alzamend Neuro

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

180 Life Sciences

Azitra

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Ensysce Biosciences

Galecto

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Oragenics

Palisade Bio

Palatin Techs

Sunshine Biopharma

SILO Pharma

Synaptogenix

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Theriva Biologics

VivoSim Labs

Longevity Health Holdings, Inc. - Common Stock

Longevity Health Holdings

Xenetic Biosciences

EF Hutton

Comments

Pasithea Therapeutics

空売り

Pasithea Therapeutics (NASDAQ:KTTA) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル